A study of whether giving iron into the veins may be helpful for patients with broken hips.

The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients – a pilot study - IVANOF1 study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-003233-34-GB

Enrollment

Registered

2012-01-04

Start date

2012-01-19

Completion date

Unknown

Last updated

2019-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia following hip fracture

Interventions

Trade Name: Venofer Product Name: Venofer 20 mg iron / ml, solution for injection or concentrate for solution for infusion. Pharmaceutical Form: Solution for injection/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary hip fracture Aged over 70 Able to consent for themselves Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 80

Exclusion criteria

Exclusion criteria: Undisplaced intracapsular fractures (very low transfusion requirements) Contra-indications to intravenous iron Currently taking anti-platelet drugs other than aspirin

Design outcomes

Primary

Measure	Time frame
Secondary Objective: To see what effects intravenous iron has on other markers of red cell production and to see whether a full scale trial is feasible.;Primary end point(s): Reticulocyte count at day 7;Timepoint(s) of evaluation of this end point: Measured each day. Primay end point is at day 7;Main Objective: To determine whether intravenous iron given in the first few days following hip fracture is effective in stimulating red cell production.	—

Measure

Time frame

Secondary Objective: To see what effects intravenous iron has on other markers of red cell production and to see whether a full scale trial is feasible.;Primary end point(s): Reticulocyte count at day 7;Timepoint(s) of evaluation of this end point: Measured each day. Primay end point is at day 7;Main Objective: To determine whether intravenous iron given in the first few days following hip fracture is effective in stimulating red cell production.

—

Secondary

Measure	Time frame
Secondary end point(s): Haematological• Haematopoietic indices: FBC, serum transferrin receptor concentrations. Collected daily for 7 days following admission. • Number of patients requiring blood transfusion during hospital admission • Transfusion index (units / patient) Patient outcome • Postoperative infectious complications • Cardiovascular complications • Length of acute hospital stay • Functional mobility at days 1 – 3: assessed using Cumulated Ambulation Score • Transfusion related costs: consumables, nursing time. • Overall acute healthcare costs: estimated from length of stay, investigations, drug costs.;Timepoint(s) of evaluation of this end point: During first 7 days for laboratory / mobility endpoints. Notes review for length of stay.	—

Measure

Time frame

Secondary end point(s): Haematological• Haematopoietic indices: FBC, serum transferrin receptor concentrations. Collected daily for 7 days following admission. • Number of patients requiring blood transfusion during hospital admission • Transfusion index (units / patient) Patient outcome • Postoperative infectious complications • Cardiovascular complications • Length of acute hospital stay • Functional mobility at days 1 – 3: assessed using Cumulated Ambulation Score • Transfusion related costs: consumables, nursing time. • Overall acute healthcare costs: estimated from length of stay, investigations, drug costs.;Timepoint(s) of evaluation of this end point: During first 7 days for laboratory / mobility endpoints. Notes review for length of stay.

—

Countries

United Kingdom

Contacts

Public ContactIain Moppett

University of Nottingham

iain.moppett@nottingham.ac.uk01158230959

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Mar 22, 2026